Hmmm. Well..if I understand the system, there goes reimbursement for Medicare mets patients. I'm gonna throw out the possibility that adjustments in delivery approaches (frequencey, time of day) might retain benefit of this drug. It's happened before. But maybe the same anti-angiogenic qualities can be attained by adjusting delivery schedules of the chemo itself to more frequent lower doses (
metronomic).